Last reviewed · How we verify
rabbit anti-thymocyte globulin - 4 doses
Rabbit anti-thymocyte globulin (rATG) depletes T lymphocytes by binding to and eliminating thymus-derived T cells, suppressing the adaptive immune response.
Rabbit anti-thymocyte globulin (rATG) depletes T lymphocytes by binding to and eliminating thymus-derived T cells, suppressing the adaptive immune response. Used for Prevention of acute organ rejection in renal transplantation, Treatment of aplastic anemia, Prevention of graft-versus-host disease in hematopoietic stem cell transplantation.
At a glance
| Generic name | rabbit anti-thymocyte globulin - 4 doses |
|---|---|
| Also known as | Thymoglobulin |
| Sponsor | University of Nebraska |
| Drug class | Polyclonal antithymocyte antibody |
| Target | T lymphocyte surface antigens (CD2, CD3, CD4, CD8, HLA-DR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
rATG is a polyclonal antibody preparation derived from immunized rabbits that targets multiple antigens on the surface of T lymphocytes. Upon administration, it binds to T cells and facilitates their removal through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, resulting in profound T cell depletion. This immunosuppressive effect is used to prevent graft rejection in transplantation and to treat certain immune-mediated conditions.
Approved indications
- Prevention of acute organ rejection in renal transplantation
- Treatment of aplastic anemia
- Prevention of graft-versus-host disease in hematopoietic stem cell transplantation
Common side effects
- Fever and chills
- Thrombocytopenia
- Leukopenia
- Infection
- Serum sickness
- Cytokine release syndrome
Key clinical trials
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1, PHASE2)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (PHASE1)
- TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (PHASE2)
- Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis (NA)
- Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: